KMDA

TentativeAI Memo

Kamada

As of 2026-10-06/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q4 plasma-supply sales • 2026-12-31

Base target: $8 / p=45% prob

Biggest risk

First-half gross margin declined to 42% from 45% year over year. Plasma collection must ramp for contracted sales, while increased rabies exposure may not persist or translate into KedRAB sales. Kamada also identifies Kedrion as KedRAB's sole U.S. distributor. [#IR-2026-08-12] [#IR-2026-09-17]

Invalidation

Break below $6 or thesis failure.

What would change my mind?

Q2 revenue rose 23% year over year to $54.9 million and adjusted EBITDA rose 29% to $14.1 million, driven chiefly by KEDRAB, VARIZIG and HEPAGAM. Commercial growth and initial plasma-supply sales could support affirmed 2026 guidance. [#IR-2026-08-12]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-06

Base target

p=45%

Bull target

$10

p=20%

Bear target

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

CYTOGAM post-marketing research and utilization
Q2 revenue rose 23% year over year to $54.9 million and adjusted EBITDA rose 29% to $14.1 million, driven chiefly by KEDRAB, VARIZIG and HEPAGAM.
Commercial growth and initial plasma-supply sales could support affirmed 2026 guidance.

BearKey bullets

A director reported September open-market sales; these Form 4 transactions do not establish operating weakness.
[#SEC-FORM4-2026-09-11] [#SEC-FORM4-2026-09-17]
CYTOGAM post-marketing findings do not establish a dated commercial milestone or quantified sales uplift.

WatchKey bullets

Q4 plasma-supply sales

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $8 (p=45%)

Target spread vs base: +32% / -24%

Scenario probabilities

Bull Target: $10 (p=20%)Base Target: $8 (p=45%)Bear Target: $6 (p=35%)

Commentary

Company updates are operationally constructive, but the packet contains no sufficient social, options, short-interest or employee-sentiment measurements; zeros above mean unavailable, not neutral observations. No verified post-results price reaction, earnings consensus surprise or analyst target revisions are available. The $8.00 anchor is dated October 5. Improved operating peer context does not resolve the valuation gap or the negative, high-uncertainty deterministic prior; this remains a cautious monitoring view.

As of 2026-10-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

CYTOGAM post-marketing research and utilization

Scenarios

Bull Target (Scenario probability)

$10 / p=20% prob

Base Target (Scenario probability)

$8 / p=45% prob

Bear Target (Scenario probability)

$6 / p=35% prob

Analysis 2026-10-06 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Q4 plasma-supply sales
Kamada expects initial Q4 2026 sales under a three-year plasma-supply agreement worth approximately $50 million. Expected Q4 sales are already included in annual guidance; collection ramp-up and delivery remain the test. [#IR-2026-07-23] Company announcement
Prob 65.00% • Move 10.00% • Priced-in 55.00%
EVENT2026-12-31
KedRAB demand conversion
Kamada says it has capacity and inventory to serve increased U.S. demand following a CDC rabies-exposure advisory. Higher exposure does not establish sustained sales growth; subsequent product sales must confirm it. [#IR-2026-09-17] Company announcement
Prob 50.00% • Move 8.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

CYTOGAM post-marketing research and utilization
2026-12-31
Kamada reported that an investigator-initiated study in high-risk lung-transplant recipients found an association between CYTOGAM use and improved outcomes. Its post-marketing research program could support utilization over time, but no dated readout or incremental sales contribution is established. The date is a monitoring horizon, not an announced milestone. [#IR-2026-08-12] Company results
Prob 40% • Move 8% • Priced-in 25%

Risks

A director reported September open-market sales; these Form 4 transactions do not establish operating weakness. [#SEC-FORM4-2026-09-11] [#SEC-FORM4-2026-09-17]
CYTOGAM post-marketing findings do not establish a dated commercial milestone or quantified sales uplift. [#IR-2026-08-12]
First-half gross margin fell to 42% from 45% despite revenue growth. [#IR-2026-08-12]
KedRAB demand may prove seasonal; Kamada relies on Kedrion as its sole U.S. distributor and needs adequate hyper-immune plasma supply. [#IR-2026-09-17]
Plasma-center ramp-up or delivery delays could defer supply-agreement revenue already included in 2026 guidance. [#IR-2026-07-23]

Peers

Symbol	Summary
ADMA	A closer operating reference than market-cap-matched clinical-stage companies: ADMA markets FDA-approved plasma-derived immune globulins and collects U.S. source plasma. Its product mix and scale still differ from Kamada's, so no valuation multiple is transferred. ADMA company results
GRFS	Grifols produces plasma-derived medicines and has an immunoglobulin franchise, making it relevant to industry demand and supply-chain monitoring. Its much larger, diversified operations make it unsuitable as a direct valuation multiple for Kamada. Grifols company results

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-06

Loading AI feed…

Symbol

Summary

ADMA

A closer operating reference than market-cap-matched clinical-stage companies: ADMA markets FDA-approved plasma-derived immune globulins and collects U.S. source plasma. Its product mix and scale still differ from Kamada's, so no valuation multiple is transferred. ADMA company results

GRFS

Grifols produces plasma-derived medicines and has an immunoglobulin franchise, making it relevant to industry demand and supply-chain monitoring. Its much larger, diversified operations make it unsuitable as a direct valuation multiple for Kamada. Grifols company results